Highlights Stallergenes Greer

Equities

STAGR

GB00BZ21RF93

Real-time Euronext Paris Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		+0.14%	+29.68%

2023	Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes	CI
2023	Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nestle Reportedly May Sell Peanut Allergy Therapy to Stallergenes	23-07-11	CI
Stallergenes Greer Ltd Initiates European Paediatric Phase III Study with Staloral Birch	23-05-25	CI
Stallergenes Greer Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-05	CI
Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy with Imperial College London Research Collaboration	22-01-17	CI
Stallergenes Greer and Aptar Pharma Announce Partnership to Develop Novel Connected Device for Allergen Immunotherapy Treatment Delivery	21-10-26	CI
Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy	21-07-09	CI
Stallergenes Greer Ltd Announces Alustal®, Subcutaneous Allergen Immunotherapy Treatment Now Available	21-06-24	CI
Stallergenes Greer and Anergis Report Successful Preclinical Study Results with COP-Virosomes as Second-Generation Allergen Immunotherapy	20-05-28	CI
Stallergenes Greer Announces Submission of A Marketing Authorization Application for STAGR320	20-05-04	CI
Ares Life Sciences I SARL completed the acquisition of remaining 16.13% stake in Stallergenes Greer plc from a group of shareholders.	19-05-15	CI
Stallergenes Greer plc Reports Unaudited Revenue Results for the First Quarter of 2019; Confirms Earnings Guidance for the Full Year 2019	19-04-17	CI
Stallergenes Greer Reports Consolidated Earnings Results for the Year Ended December 31, 2018; Provides Earnings Guidance for the Full Year 2019	19-03-21	CI
Ares Life Sciences I SARL reached an agreement to acquire remaining 16.13% stake in Stallergenes Greer plc from a group of shareholders for approximately €120 million.	19-03-20	CI
Stallergenes Greer plc Announces Phase III Trial for its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved its Primary Endpoint	18-11-20	CI
Stallergenes Greer Announces U.S. FDA Approval of Pediatric Indication Extension for Oralair Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy	18-11-14	CI
Stallergenes Greer plc Reports Unaudited Consolidated Earnings Results for the First Half Ended June 30, 2018; Provides Earnings Guidance for the Full Year of Fiscal 2018	18-08-29	CI
Stallergenes Greer plc Revises Earnings Guidance for the Year 2018	18-06-07	CI
Stallergenes Greer Plc Announces Audited Consolidated Earnings Results for the Second Half and Full Year Ended December 31, 2017; Provides Earnings Guidance for the Fiscal 2018	18-03-22	CI
Stallergenes Greer Plc acquired Medic Savoure Limited.	17-10-01	CI
Stallergenes Greer Plc Announces Health Canada Accepts for Review the its New Drug Submission for STG320	17-09-26	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Stallergenes Greer

Equities

STAGR

GB00BZ21RF93

Highlights

Filters